MyPrurigoTeam

Which treatment works better between Nemluvio (nemolizumab) and Dupixent (dupilumab) for prurigo nodularis?

There isn't a clear consensus on which works better because they haven't been directly compared in head-to-head studies. Both are FDA-approved biologics for prurigo nodularis, but they work differently and may Show Full Answer

Which treatment works better between Nemluvio (nemolizumab) and Dupixent (dupilumab) for prurigo nodularis?

There isn't a clear consensus on which works better because they haven't been directly compared in head-to-head studies. Both are FDA-approved biologics for prurigo nodularis, but they work differently and may respond differently for each person.

Here's what the research shows for each:

Nemluvio (nemolizumab):
* Targets IL-31 signaling, which is a key driver of itch
* In studies, about 58% had significant itch relief by 16 weeks
* Around 30% achieved near-total or total skin clearance by 24 weeks
* Over 90% saw at least a four-point drop in itch levels after 100 weeks
* Given as an injection once every four weeks

Dupixent (dupilumab):
* Targets IL-4 and IL-13 signaling, addressing inflammation differently
* Given as an injection every other week
* Was the first biologic approved for prurigo nodularis

Since prurigo nodularis shows up very differently in different people—with varying nodule types, severity, and skin characteristics—what works better can vary from person to person. Some may respond better to one medication over the other.

The best approach is to talk with your dermatologist about which might be right for you based on your specific symptoms, treatment goals, and how you've responded to other treatments.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

90% Have Less Itch After 2 Years on Nemolizumab, Study Finds

58% Saw Itch Relief and 31% Had Skin Clearance From Nemolizumab